Tranexamic Acid Protects Ovary and Testis Functions and Ameliorates Osteoporosis in Mice.


Journal

Pharmacology
ISSN: 1423-0313
Titre abrégé: Pharmacology
Pays: Switzerland
ID NLM: 0152016

Informations de publication

Date de publication:
2020
Historique:
received: 26 11 2019
accepted: 26 01 2020
pubmed: 30 4 2020
medline: 18 3 2021
entrez: 30 4 2020
Statut: ppublish

Résumé

In a rapidly aging society, the number of people suffering from osteoporosis keeps increasing. However, effective prevention strategies for osteoporosis are not yet currently available. In this study, we examined the ameliorative effects of tranexamic acid on osteoporosis in 24-month-old mice. During the study period, mice were orally administered tranexamic acid 3 times per week. Bone mineral density, which is a parameter of osteoporosis, was improved following tranexamic acid administration. In addition, female mice evidenced a stronger phenotypic improvement than male mice. In female mice treated with tranexamic acid, ovary abnormalities were reduced. Furthermore, the levels of transforming growth factor-β, hyaluronic acid, CD44, reactive oxygen species, and apoptosis, as well as the number of infiltrated neutrophils and macrophages in the ovary were lower than those in the control or solvent-administered mice. In addition, 17β-estradiol levels in blood increased when compared with the control or solvent-treated mice. In addition, administration of tranexamic acid to 24-month-old male mice decreased the level of apoptosis in the testis. However, the levels of 17β-estradiol and testosterone in blood increased compared with the control or solvent-administered mice. The use of tranexamic acid had an ameliorative effect on osteoporosis, possibly by protecting ovaries and testes.

Identifiants

pubmed: 32348988
pii: 000506233
doi: 10.1159/000506233
doi:

Substances chimiques

Protective Agents 0
Reactive Oxygen Species 0
Transforming Growth Factor beta 0
Testosterone 3XMK78S47O
Estradiol 4TI98Z838E
Tranexamic Acid 6T84R30KC1
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

652-661

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Keiichi Hiramoto (K)

Department of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan, hiramoto@suzuka-u.ac.jp.

Hirotaka Oikawa (H)

Department of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan.

Yurika Yamate (Y)

Department of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan.

Eisuke F Sato (EF)

Department of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH